Sai Parenteral's IPO GMP History
Sai Parenteral's IPO has been listed on April 2, 2026 at a listing price of ₹400, against the issue price of ₹392 — a gain of ₹8 (+2.04%). The GMP peaked at ₹00 on 1 April 2026 and reached a low of ₹00 on 1 April 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Sai Parenteral's IPO raised ₹409 Cr. through its IPO at a price band of ₹372 to ₹392 per share, with a lot size of 38 shares. The IPO was open for subscription from 24 Mar 2026 to 27 Mar 2026.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 3 Sep, 2:08 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 01 Apr 2026 | ₹ 0 | — | -- | — | — |
| 31 Mar 2026 | ₹ 0 | — | -- | — | — |
| 30 Mar 2026 | ₹ 0 | — | -- | — | — |
| 29 Mar 2026 | ₹ 0 | — | -- | — | — |
| 28 Mar 2026 | ₹ 0 | — | -- | — | — |
| 25 Mar 2026 | ₹ 0 | — | -- | — | — |
| 24 Mar 2026 | ₹ 0 | — | -- | — | — |
| 23 Mar 2026 | ₹ 0 | — | -- | — | — |
| 21 Mar 2026 | ₹ 0 | — | -- | — | — |
| 20 Mar 2026 | ₹ 0 | — | -- | — | — |
| 19 Mar 2026 | ₹ 0 | — | -- | — | — |
| 18 Mar 2026 | ₹ 0 | — | -- | — | — |
Sai Parenteral's IPO dates
Key dates from opening to listing. Today is 3 October.
- Open 24 Mar 2026
- Close 27 Mar 2026
- Allotment 30 Mar 2026
- Refund/credit 01 Apr 2026
- Listing 02 Apr 2026
Sai Parenteral's IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹392 |
|---|---|
| Listing gain / loss | +₹8 per share |
| Listing date | 02 Apr, 2026 |
| Actual listing price | ₹400 (+2.04%) |
Is Sai Parenteral's IPO GMP reliable?
Grey market premium for Sai Parenteral's IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Sai Parenteral's IPO full review for a fundamentals-based assessment before making any grey market trades.
Sai Parenteral's IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Sai Parenteral's IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Sai Parenteral's IPO
Sai Parenteral Limited is an Indian pharmaceutical company engaged in the manufacturing of a wide range of sterile formulations. The company was established with the objective of providing high-quality and affordable injectable medicines, catering to both domestic and international markets. Over the years, it has built a strong presence in the pharma industry by focusing on compliance, quality standards, and consistent product delivery. The company is promoted by experienced professionals with deep domain knowledge in pharmaceutical manufacturing and regulatory requirements, which has helped in establishing a reliable operational framework.
The company’s product portfolio primarily includes injectable formulations such as antibiotics, analgesics, and other therapeutic drugs used in hospitals and healthcare institutions. It follows a business model that combines contract manufacturing and direct marketing, enabling it to serve both institutional buyers and third-party clients. Sai Parenteral emphasises quality control, modern manufacturing facilities, and adherence to regulatory standards, which supports its long-term growth. By maintaining strong relationships with clients and focusing on operational efficiency, the company aims to expand its footprint in the competitive pharmaceutical sector.
Frequently asked
What is the GMP of Sai Parenteral's IPO?
The current Grey Market Premium (GMP) of Sai Parenteral's IPO is not yet started or active in the market.
What is the Kostak Price of Sai Parenteral's IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Sai Parenteral's IPO is not available.
What is the Subject to Sauda Price of Sai Parenteral's IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Sai Parenteral's IPO?
Sai Parenteral's IPO listed on April 2, 2026 at ₹400, against the issue price of ₹392 — a gain of +2.04%.
How did the GMP of Sai Parenteral's IPO trend before listing?
The GMP of Sai Parenteral's IPO was stable in its final days before listing. The GMP peaked at ₹00 on 1 April 2026. View the day-wise table above for the complete GMP history.
Explore Sai Parenteral's IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
